Indication
Congenital Adrenal Hyperplasia
16 clinical trials
15 products
2 drugs
Clinical trial
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study of Chronocort Compared With Immediate-Release Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal HyperplasiaStatus: Completed, Estimated PCD: 2024-02-02
Product
ChronocortProduct
CortefClinical trial
A Phase 3 Open-Label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal HyperplasiaStatus: , Estimated PCD: 2024-12-31
Product
AAV BBP-631Clinical trial
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 GeneStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects With Classic Congenital Adrenal HyperplasiaStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Tildacerfont/PlaceboClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects With Classic Congenital Adrenal HyperplasiaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)Status: Recruiting, Estimated PCD: 2025-03-01
Product
CRN04894Clinical trial
A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal HyperplasiaStatus: Recruiting, Estimated PCD: 2024-12-01
Product
TildacerfontClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label TreatmentStatus: Active (not recruiting), Estimated PCD: 2023-07-19
Product
PlaceboProduct
CrinecerfontClinical trial
A Phase III Extension Study of Efficacy, Safety and Tolerability of Chronocort® in the Treatment of Congenital Adrenal HyperplasiaStatus: Completed, Estimated PCD: 2022-07-13
Product
HydrocortisoneClinical trial
A Multi-site, Open-label, Sequential-group, Multiple-ascending-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Patients With Congenital Adrenal HyperplasiaStatus: Recruiting, Estimated PCD: 2024-12-28
Product
Lu AG13909Clinical trial
A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase DeficiencyStatus: , Estimated PCD: 2025-01-23
Clinical trial
An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal HyperplasiaStatus: Completed, Estimated PCD: 2024-04-01
Product
FludrocortisoneProduct
LetrozoleProduct
FlutamideClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label TreatmentStatus: Active (not recruiting), Estimated PCD: 2023-03-10
Drug
VarlilumabClinical trial
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal HyperplasiaStatus: Completed, Estimated PCD: 2016-12-01
Product
Solu-CortefClinical trial
A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase DeficiencyStatus: Withdrawn, Estimated PCD: 2026-01-01
Clinical trial
Interval Bolus Delivery of Subcutaneous Hydrocortisone Via Infusion Pump in Children With Congenital Adrenal HyperplasiaStatus: Completed, Estimated PCD: 2023-02-23